Related Experiment Video
Updated: Aug 9, 2026
10:16
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Therapeutic goals in Gaucher disease
1Yale University School of Medicine, Internal Medicine, New Haven, CT 06520, USA.
La Revue De Medecine Interne
|April 29, 2006
Summary
Enzyme replacement therapy (ERT) is crucial for managing Gaucher disease, offering significant benefits when initiated early. This lifelong treatment, exemplified by Cerezyme, effectively addresses key disease manifestations and complications.
Area of Science:
- Biochemistry
- Genetics
- Internal Medicine
Background:
- Gaucher disease is a rare genetic disorder.
- Therapeutic goals aim to reverse phenotype, prevent complications, and improve quality of life.
Purpose of the Study:
- To outline evidence-based therapeutic goals for Gaucher disease management.
- To emphasize the optimal timing and benefits of enzyme replacement therapy (ERT).
Main Methods:
- Review of European and American expert guidelines.
- Analysis of the efficacy and safety of Cerezyme (imiglucerase) as a standard of care.
Main Results:
- ERT is most effective when administered during the asymptomatic phase.
- Cerezyme effectively ameliorates bleeding, reverses organomegaly, improves skeletal damage, and prevents bone crises.
- ERT demonstrates a high safety profile with >99% tolerability at 3 years.
Conclusions:
- Lifelong ERT is essential for Gaucher disease management.
- Treatment should not be interrupted without careful disease monitoring.
- Early intervention with ERT optimizes patient outcomes and quality of life.
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...